Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2023-12-04 Major Shareholding Noti…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Change in substantial holding 5 pages 161.7KB
Major Shareholding Notification Classification · 100% confidence The document is a disclosure of movement of 1% or more in substantial holding or change in nature of relevant interest under the Financial Markets Conduct Act 2013. It details shareholding percentages, transactions, and related parties. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about shareholding changes, fitting the definition of a Major Shareholding Notification (MRQ). The length and content confirm it is not a brief announcement or a report publication notice, but a substantive notification of shareholding changes.
2023-12-04 English
SPH Notice – ANZ New Zealand Investments Limited
Major Shareholding Notification Classification · 100% confidence The document is a detailed disclosure of movements in substantial shareholdings, specifically reporting changes of 1% or more in the holdings of ANZ New Zealand Investments Limited, ANZ Bank New Zealand Limited, and ANZ Custodial Services New Zealand Limited. It includes transaction details, percentages held, and nature of relevant interests. The document references sections of the Financial Markets Conduct Act 2013 and is addressed to NZX Limited, indicating it is a regulatory filing related to shareholding notifications. It is not an annual report, earnings release, or management report, nor is it a proxy or voting result announcement. The content fits the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds. The document length and detail confirm it is not a brief announcement or certification only. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2023-11-30 English
Financial Results for the Half Year to 30 September 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2023' and contains detailed financial and operational data for the half-year period ending September 30, 2023. It includes revenue figures, net loss, cash balances, strategic highlights, and outlook commentary. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is over 10,000 characters, so it is not a brief announcement or a report publication notice. There is no indication that this is a full Annual Report (10-K) or an earnings release (which typically contains only key highlights). The detailed financial and operational discussion aligns with the definition of an Interim / Quarterly Report (IR). H1 2024
2023-11-22 English
Financial Results for the Half Year to 30 September 2023 57 pages 10.3MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2023' and contains detailed financial and performance highlights for the half year period ending September 30, 2023. It includes revenue figures, net loss, cash position, strategic highlights, and outlook commentary. The document also mentions a conference call for investors and provides an investor presentation. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release with only key highlights. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2023-11-22 English
Kaiser Permanente EMR Integration goes live
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the launch of the integration of Pacific Edge's Cxbladder tests within Kaiser Permanente's Electronic Medical Records system. It focuses on a partnership, product integration, and operational details rather than financial results, regulatory filings, or shareholder information. There is no indication of financial statements, earnings data, management changes, or voting results. The content is promotional and informative about a business development and partnership, typical of a Capital/Financing Update or general corporate announcement. Given the nature of the announcement about a significant business development and partnership, the most appropriate classification is Capital/Financing Update (CAP).
2023-11-14 English
Kaiser Permanente EMR Integration goes live 3 pages 115.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of the integration of Pacific Edge's Cxbladder tests within Kaiser Permanente's Electronic Medical Records system. It focuses on the operational and clinical benefits of this integration, describing the partnership and its impact on patient care. There are no financial statements, regulatory filings, voting results, or management changes discussed. The content is an update on a business development and partnership rather than a formal financial or regulatory report. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS).
2023-11-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.